A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthrit

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa

CNBC Final trades: Lebenthal picks Micron, Snipe chooses Palo Alto, Brown expects Apple's good s

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth expl

Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that

Shares of Quantinuum slide after rallying since IPO. Analysts weigh in.

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch

The committee is recommending that no new patients start treatment with Tavneos and that existing pa

The European Medicines Agency on ‌Friday recommended revoking the marketing authorisation for Amgen'

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics

Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price targe

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises

Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDY